Skip to main content

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us

https://otc.duke.edu/wp-content/uploads/2023/10/gilhuly-story-2023-featured-image.png

Gilhuly Accelerator Fund Invests Over $1M in Duke Inventor Projects in its Inaugural Year

The Duke community, led by Trustee Ned Gilhuly, is supporting Duke inventors with its newest translational fund dedicated to accelerating the development of early-stage technologies with high commercial potential.

Read More

https://otc.duke.edu/wp-content/uploads/2023/10/Soman-and-Dennis-thumbnail-play.png

Watch: Translation & Commercialization as a collaborative, creative process

OTC licensing managers are creative partners to Duke inventors – just ask pathologist Dr. Soman Abraham and OTC’s Dr. Dennis Thomas.

Read More

https://otc.duke.edu/wp-content/uploads/2023/10/2023-finalists-grand-and-exection-1200x628-1.png

MedTech Innovator Announces 2023 Grand Prize Finalists

Duke start-up Sparta Biomedical has been selected as one of five AdvaMed Accel and MedTech Innovator Execution Award Finalists.

Read More

https://otc.duke.edu/wp-content/uploads/2023/09/TVD-story-featured-image.png

Setting Rivalries Aside, University Startups Come Together to Pitch 50+ Elite Investors at Triangle Venture Day: Therapeutics 2023

The recurring event offers venture capital investors from across the country an exclusive look at therapeutics startups launching from Duke, UNC, NC State University, and the North Carolina Biotechnology Center.

Read More

https://otc.duke.edu/wp-content/uploads/2023/09/menarini-stemline-logos.png

European Commission Approves Menarini Group’s ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

ORSERDU is based on technology licensed out of the lab of Dr. Donald McDonnell (Pharmacology and Cancer Biology, SOM).

Read More

https://otc.duke.edu/wp-content/uploads/2023/01/11B5C88A-E824-48AC-B630-1E8815D4E436.jpg

Durham-based Restor3d raises $17 million

restor3d, a Duke spinout from the lab of Prof Ken Gall (MEMS, Pratt), is also a Duke Capital Partners portfolio company.

Read More

https://otc.duke.edu/wp-content/uploads/2023/08/Sparta_Biomedical__Logo.jpg

Sparta Biomedical Closes an Oversubscribed Convertible Round to Advance its Breakthrough Device

Sparta Biomedical, a Duke start-up and Duke Capital Partners portfolio company, was founded around technology developed by lead inventor Professor Benjamin Wiley (Chemistry, Trinity), along with Professor Ken Gall (MEMS, Pratt), Professor Matt Becker (Chemistry,…

Read More

https://otc.duke.edu/wp-content/uploads/2023/08/North-Carolina-Biotechnology-Center-NCBC.png

NCBiotech Awards $2.75 Million in Grants, Loans in Latest Quarter

Two Duke start-ups received loans & four Duke projects received Translational Research Grants. Recipients hail from across the university!

Read More

https://otc.duke.edu/wp-content/uploads/2023/08/Sparta_Biomedical__Logo.jpg

Sparta Biomedical Celebrates Prestigious Recognition in MedTech and Significant Milestone

Sparta Biomedical, a Duke start-up and Duke Capital Partners portfolio company, was founded around technology developed by lead inventor Professor Benjamin Wiley (Chemistry, Trinity), along with Professor Ken Gall (MEMS, Pratt), Professor Matt Becker (Chemistry,…

Read More